Two N.J, pharma companies leading search for Ebola vaccine

Biopharmaceutical companies generate billions in economic activity for New Jersey, but don’t expect their latest, most high-profile venture — tackling the Ebola epidemic — to add much to their bottom line.

Industry leaders say they have a greater goal in mind.

“The real purpose is not to make money or not lose money. The real purpose is to respond to the public health need,” said Dr. Mark Feinberg, chief public health and science officer for vaccines at Merck & Co. in Kenilworth.

Read more at NorthJersey.com

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s